From the perspective of the putaminal AADC gene therapy for Parkinson’s disease wherein the degeneration of the nigrostriatal dopaminergic pathway in the cortico-basal ganglia network leads to the development of motor symptoms, the central mechanism underlying the motor functional recovery by the putaminal AADC gene transfer has been assumed to be the restoration of the motor cortico-putaminal network to recover motor executive function.27 The gene discussed is DDC; the disease is Parkinson disease.